Ran et al. designed and synthesized a series of pyrazolopyrimidine derivatives as BTK inhibitors and evaluated their antitumor activity against mantle cell lymphoma (MCL) cell lines [69]. This evidence concerns the gene BTK and mantle cell lymphoma.